---
figid: PMC5713354__ijms-18-02385-g002
figlink: /pmc/articles/PMC5713354/figure/ijms-18-02385-f002/
number: F2
caption: 'The current possible strategies to bypass AVPR2 mutations responsible for
  X-linked NDI. The most recurrent mutations of AVPR2 responsible for X-linked NDI
  are class II mutations producing full-length misfolded proteins trapped in the endoplasmic
  reticulum (ER), although retaining intrinsic functionality. A lack of AVPR2 basolateral
  expression prevents AVP signaling and AQP2 exocytosis (grey dotted lines). Possible
  therapeutic strategies (full lines) for treating X-linked NDI are focused on: (1)
  the use of chemical chaperones aiding protein folding and inducing export from the
  ER; nonpeptide AVPR2 antagonists, like vaptans, that stabilize receptor conformation
  in the ER, thus allowing it to bypass the ER quality control mechanism; and nonpeptide
  AVPR2 agonists that promote interaction with adenylyl cyclase, thus increasing cAMP
  concentration (+). (2) Activation of the cAMP pathway by stimulating other G proteins-coupled
  receptors (GPCRs) coupled to Gs/adenylyl cyclase expressed in collecting duct principal
  cells such as secretin (SCT), calcitonin (CT), E-prostanoid receptors (EP2/EP3/EP4)
  and β3-adrenoreceptor; the inhibition of phosphodiestherases (PDE) to increase basal
  cAMP levels (+). (3) The activation of the cyclic guanosine monophosphate (cGMP)
  pathway, promoting AQP2 exocytosis either by stimulating guanylyl cyclase or by
  inhibiting PDE. (4) The inhibition of epidermal growth factor receptor (EGFR), which
  counteracts AVP-mediated AQP2 exocytosis by a not fully elucidated mechanism. (5)
  The activation of AMP-activated protein kinase (AMPK) promoting AVP-independent
  AQP2 phosphorylation. (6) Thiazolidinediones (Rosiglitazone) likely promotes Ca2+
  influx that triggers AQP2 exocytosis at the plasma membrane in the absence of AQP2
  phosphorylation. (7) Statins treatment that inhibits RhoA, promotes cortical actin
  depolymerization, and facilitates the constitutive exocytosis of AQP2 at the apical
  membrane.'
pmcid: PMC5713354
papertitle: 'Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible
  Treatment. An Update.'
reftext: Serena Milano, et al. Int J Mol Sci. 2017 Nov;18(11):2385.
pmc_ranked_result_index: '224156'
pathway_score: 0.8888605
filename: ijms-18-02385-g002.jpg
figtitle: Current possible strategies to bypass AVPR2 mutations responsible for X-linked
  NDI
year: '2017'
organisms:
- Mus musculus
- Rattus norvegicus
- Saccharomyces cerevisiae
- Xenopus laevis
- Homo sapiens
- Oryctolagus cuniculus
ndex: f91353aa-df12-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5713354__ijms-18-02385-g002.html
  '@type': Dataset
  description: 'The current possible strategies to bypass AVPR2 mutations responsible
    for X-linked NDI. The most recurrent mutations of AVPR2 responsible for X-linked
    NDI are class II mutations producing full-length misfolded proteins trapped in
    the endoplasmic reticulum (ER), although retaining intrinsic functionality. A
    lack of AVPR2 basolateral expression prevents AVP signaling and AQP2 exocytosis
    (grey dotted lines). Possible therapeutic strategies (full lines) for treating
    X-linked NDI are focused on: (1) the use of chemical chaperones aiding protein
    folding and inducing export from the ER; nonpeptide AVPR2 antagonists, like vaptans,
    that stabilize receptor conformation in the ER, thus allowing it to bypass the
    ER quality control mechanism; and nonpeptide AVPR2 agonists that promote interaction
    with adenylyl cyclase, thus increasing cAMP concentration (+). (2) Activation
    of the cAMP pathway by stimulating other G proteins-coupled receptors (GPCRs)
    coupled to Gs/adenylyl cyclase expressed in collecting duct principal cells such
    as secretin (SCT), calcitonin (CT), E-prostanoid receptors (EP2/EP3/EP4) and β3-adrenoreceptor;
    the inhibition of phosphodiestherases (PDE) to increase basal cAMP levels (+).
    (3) The activation of the cyclic guanosine monophosphate (cGMP) pathway, promoting
    AQP2 exocytosis either by stimulating guanylyl cyclase or by inhibiting PDE. (4)
    The inhibition of epidermal growth factor receptor (EGFR), which counteracts AVP-mediated
    AQP2 exocytosis by a not fully elucidated mechanism. (5) The activation of AMP-activated
    protein kinase (AMPK) promoting AVP-independent AQP2 phosphorylation. (6) Thiazolidinediones
    (Rosiglitazone) likely promotes Ca2+ influx that triggers AQP2 exocytosis at the
    plasma membrane in the absence of AQP2 phosphorylation. (7) Statins treatment
    that inhibits RhoA, promotes cortical actin depolymerization, and facilitates
    the constitutive exocytosis of AQP2 at the apical membrane.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDE2A
  - PDE1A
  - PDE1C
  - SCT
  - PDE7B
  - RHOA
  - PDE1B
  - PDE6B
  - PDE3A
  - PDE11A
  - PTGER3
  - PDE4D
  - PDE10A
  - PDE8A
  - PDE9A
  - PRKAG3
  - PRKAA1
  - PRKAA2
  - PRKAB2
  - PRKAG1
  - ACTC1
  - PRKAR2A
  - PRKAR2B
  - ACTG2
  - ACTA2
  - ACTA1
  - PRKAB1
  - PRKAG2
  - PDE7A
  - AQP2
  - ACTG1
  - PDE8B
  - PRKACA
  - PTGER4
  - PDE4C
  - ACTB
  - EGFR
  - PDE4A
  - PRKACB
  - PDE6A
  - PDE6C
  - PRKAR1A
  - PDE4B
  - PRKACG
  - PDE3B
  - PRKAR1B
  - AVPR2
  - AVP
  - Metformin
  - rolipram
genes:
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE2A
  entrez: '5138'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE1A
  entrez: '5136'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE1C
  entrez: '5137'
- word: SCT,CT,
  symbol: SCT
  source: hgnc_symbol
  hgnc_symbol: SCT
  entrez: '6343'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE7B
  entrez: '27115'
- word: RhoA
  symbol: RhoA
  source: hgnc_alias_symbol
  hgnc_symbol: RHOA
  entrez: '387'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE1B
  entrez: '5153'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE6B
  entrez: '5158'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE3A
  entrez: '5139'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE11A
  entrez: '50940'
- word: EP2/EP3/EP4ligands
  symbol: EP3
  source: hgnc_alias_symbol
  hgnc_symbol: PTGER3
  entrez: '5733'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE4D
  entrez: '5144'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE10A
  entrez: '10846'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE8A
  entrez: '5151'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE9A
  entrez: '5152'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG3
  entrez: '53632'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA1
  entrez: '5562'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA2
  entrez: '5563'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB2
  entrez: '5565'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG1
  entrez: '5571'
- word: actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTC1
  entrez: '70'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2A
  entrez: '5576'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2B
  entrez: '5577'
- word: actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTG2
  entrez: '72'
- word: actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTA2
  entrez: '59'
- word: actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTA1
  entrez: '58'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB1
  entrez: '5564'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG2
  entrez: '51422'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE7A
  entrez: '5150'
- word: AQP2
  symbol: AQP2
  source: hgnc_symbol
  hgnc_symbol: AQP2
  entrez: '359'
- word: actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTG1
  entrez: '71'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE8B
  entrez: '8622'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACA
  entrez: '5566'
- word: EP2/EP3/EP4
  symbol: EP4
  source: hgnc_alias_symbol
  hgnc_symbol: PTGER4
  entrez: '5734'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE4C
  entrez: '5143'
- word: actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTB
  entrez: '60'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE4A
  entrez: '5141'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACB
  entrez: '5567'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE6A
  entrez: '5145'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE6C
  entrez: '5146'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1A
  entrez: '5573'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE4B
  entrez: '5142'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACG
  entrez: '5568'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE3B
  entrez: '5140'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1B
  entrez: '5575'
- word: AVPR2
  symbol: AVPR2
  source: hgnc_symbol
  hgnc_symbol: AVPR2
  entrez: '554'
- word: AVP
  symbol: AVP
  source: hgnc_symbol
  hgnc_symbol: AVP
  entrez: '551'
chemicals:
- word: Metformin
  source: MESH
  identifier: D008687
- word: rolipram
  source: MESH
  identifier: D020889
diseases: []
figid_alias: PMC5713354__F2
redirect_from: /figures/PMC5713354__F2
figtype: Figure
---
